Gemcitabine + nab-paclitaxel as first-line chemotherapy for Japanese patients with advanced pancreatic cancer in real-world clinical practice: a re...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter T. Yamaguchi
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors T. Yamaguchi1, H. Ueno2, M. Sasaki2, Y. Sakamoto2, S. Kondo2, C. Morizane2, T. Okusaka2
  • 1National Cancer Center Hospital, Chuo-ku, Japan, /
  • 2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan, /

Abstract

In the international phase III study (MPACT study) and Japanese phase I/II study (J-0107 study) of metastatic pancreatic cancer, gemcitabine (G) + nab-paclitaxel (nab-P) therapy demonstrated favorable results; however, there is limited information regarding its clinical use. We aimed to evaluate the efficacy and safety of GN therapy in clinical practice.